Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD
Sponsor: Assiut University
Summary
the effect of Dapagliflozin on erythropoiesis, iron metabolism and inflammatory markers in CKD with Type 2 DM-Compare between effect of placebo and dapagliflozin on erythropoiesis, iron metabolism and inflammation markers in CKD with Type 2 DM.
Official title: English Title of Research Project: Effects of Dapagliflozin on Inflammatory Markers, Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2025-03-01
Completion Date
2027-05-01
Last Updated
2025-02-11
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin (DAPA)
patient will recive dapagliflozin for 24 week to improvement of eGFR on CKD patients
Placebo
type 2 diabetic patients with chronic kidney diseases will recive placebo for 24 weeks